Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + Epirubicin vs Docetaxel + Capecitabine in Metastatic Breast Cancer
NCT00429871Phase 3Completed
- Sponsor
- Hellenic Oncology Research Group
- Start
- May 2002
- Primary completion
- Nov 2007
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of epirubicin, capecitabine in breast cancer, sponsored by Hellenic Oncology Research Group. Started May 2002; status: completed.
02
Drugs
epirubicincapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00429871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00429871.